Global C-Reactive Protein (CRP) Testing Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type (Immunoturbidimetric Method, ELISA, Chemiluminescence, Spectrometry), By Application (Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Lupus, Others), By End Users (Hospitals And Clinics, Diagnostic Centres), And By Geography - Forecasts From 2022 To 2027

The C-Reactive Protein (CRP) Testing market was valued at US$1.856 billion in 2020 and is expected to grow at a CAGR of 2.43% over the forecast period to reach a total market size of US$2.196 billion by 2027.

Tests for C-Reactive Protein measure levels of this protein in the body. An increase in C-reactive protein levels in the body can be attributed to inflammation. The liver produces this protein. Inflammatory diseases and infections are identified and tracked by C-reactive protein tests, which include cancers, cardiovascular disease, arthritis, etc. The tests estimate whether someone is at risk of having a heart attack or stroke. As cardiovascular diseases have become more prevalent and as tests are becoming more complex, this market is being driven by these factors. As reported by the WHO,  worldwide, cardiovascular diseases (CVDs) kill about 17.9 million people each year. Numerous opportunities exist in the market, including the growing application of these tests, point-of-care testing, increased population coverage, and increased awareness of health care, particularly in developing countries.

The market is also expected to grow due to an increase in funds provided by the government to academic research institutions and individuals. The market growth is further anticipated to be supported by various initiatives by international organizations, including WHO and NIH, that aim to prevent and treat chronic disorders such as cancer and cardiovascular diseases.

Globally, the market for C-reactive protein tests will grow because of the rising prevalence of inflammatory disorders, the increasing prevalence of endometriosis in women, and technological advancements in diagnostic tests. A large number of chronic diseases are thought to be triggered by chronic inflammation, including lupus, ulcerative colitis, rheumatoid arthritis, and others. According to the Centers for Disease Control and Prevention (CDC) 2016 report, it is estimated that by 2040, approximately 78 million (26%) of US adults aged 18 and up will have arthritis.   Furthermore, this market's growth would be challenged by the lack of public awareness.

Growth Factor

• Increase in Cardiovascular Disease

It is urgently necessary to develop a quick and accurate method for diagnosing cardiovascular diseases, given their high prevalence. C-reactive protein can therefore be used for the detection of CVD due to the development of atherosclerosis, in which cholesterol is deposited inside blood vessel walls, leading to inflammation. As a result, CRP levels are higher in patients with cardiovascular disease.  Consequently, these CRP assays can detect low CRP levels, which are sensitive. Because cardiovascular diseases are increasingly prevalent, researchers are likely to pursue evaluations of CRP for cardiovascular disorders. According to the World Heart Federation, coronary heart disease is the leading cause of death in the world. There are an estimated 3.8 million males and 3.4 million females who die of coronary heart disease every year. More than 80% of deaths occur in low- and middle-income countries.  Approximately 356,000 cardiac arrests occur in the U.S. outside of hospitals every year, of which 90% are fatal, according to data from the American Heart Association 2019. It is for this reason that clinicians are increasingly implementing C-reactive protein testing. Hence, these factors combined are causing the cardiovascular diseases segment to grow at a steady pace over the forecast period.

Additionally, many research and development projects are conducted by universities and other organizations. For example,  a group of researchers from the University of Hong Kong has developed a real-time, flexible sensing device that can directly measure CRP blood levels. With this sensor, inflammation testing is 30 times faster than usual. Incidents such as these are a major factor contributing to the growth of the C-reactive protein testing market.

Restrain:

• High cost and low public awareness:

CRP testing instruments, however, are expensive. High costs will constrain the market during the given period. Also, the lack of qualified professionals in the field will hinder the market for CRP tests during the given period. In addition, low public awareness about the CRP test, as well as its low specificity in diagnosing a particular disease, are expected to restrain the market’s growth.

COVID-19's Impact on the C-Reactive Protein (CRP) Testing Market:

Patients with COVID-19 had CRP levels between 20 and 50 mg/L, which is significantly higher than the average. Patients with severe COVID-19 experienced elevated levels of CRP by 86%. CRP levels were significantly higher in patients with severe disease than in milder or less severe cases. (Source: ncbi.nlm.nih.gov). A measure of CRP has been shown to be a valuable tool in determining the possibility of progression of COVID-19 infection in adults. A result of this is that it is being adopted more widely in both primary and secondary care. Since COVID-19 is not going extinct anytime soon, the market is expected to further grow in revenue over the forecast period.

Global C-Reactive Protein (CRP) Testing Market Scope:

Market Segmentation

• By Type
  • Immunoturbidimetric method
  • ELISA
  • Chemiluminescence
  • Spectrometry 
• By Application
  • Cardiovascular diseases
  • Cancer
  • Rheumatoid Arthritis
  • Lupus
  • Others
• By End Users
  • Hospitals and Clinics
  • Diagnostic Centres
• By Geography
  • North America
    • United States
    • Canada
    • Others
  • South America
    • Brazil
    • Argentina
    • Others 
  • Europe
    • United Kingdom
    • Germany
    • France
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • China
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Japan
    • Others

Frequently Asked Questions (FAQs)

Q1. What will be the C-reactive protein (CRP) testing market size by 2027?
A1. The global C-reactive protein testing market is expected to reach a total market size of US$2.196 billion in 2027.

Q2. What is the size of the global C-reactive protein (CRP) testing market?
A2. C-Reactive Protein (CRP) Testing Market was valued at US$1.856 billion in 2020.

Q3. What are the growth prospects for the C-reactive protein testing market?
A3. The C-reactive protein (CRP) testing market is expected to grow at a CAGR of 2.43% over the forecast period.

Q4. How is the global C-reactive protein testing market segmented?
A4. The C-reactive protein (CRP) testing market has been segmented by type, application, end-users, and geography.

Q5. What factors are anticipated to drive the C-reactive protein testing market growth?
A5. The C-reactive protein testing market is also expected to grow due to an increase in funds provided by the government to academic research institutions and individuals.